Responses
Scientific Abstracts
Poster Presentations
Thursday, 04 June 2020
Rheumatoid arthritis - biological DMARDs
THU0176 OLOKIZUMAB IMPROVES PATIENT REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: RESULTS FROM THE DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE III STUDY (CREDO-1)
Compose a Response to This Article
Other responses
No responses have been published for this article.